Search

Displaying results 3961 - 3970 of 10000 in total
  1. Drug

    Pyridoxal phosphate

    go.drugbank.com/drugs/DB00114
    ApprovedInvestigationalNutraceutical

    This is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is tra...

    Mixtures: Enl, Xyzbac GCategories: Vitamin B Complex
  2. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  3. Drug

    Diethylcarbamazine

    go.drugbank.com/drugs/DB00711
    ApprovedInvestigationalVet approvedWithdrawn

    An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.

  4. Target

    C-C motif chemokine 5

    go.drugbank.com/bio_entities/BE0000975
    TargetHumans

    Recombinant RANTES protein induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). … The second processed form RANTES(4-68) exhibits reduced chemotactic and HIV-suppressive activity compared with RANTES(1-68) and RANTES(3-68) (PubMed:1380064, PubMed:15923218, PubMed:16791620, PubMed:8525373

    Synonyms: SIS-delta
  5. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

  6. Drug

    Curcuma xanthorrhiza oil

    go.drugbank.com/drugs/DB11265
    ApprovedNutraceutical

    _Curcuma xanthorrhiza_ oil is found as an active ingredient in cosmetic and hygienic products, and marketing of products containing _Curcuma xanthorrhiza_ oil is authorized in some European countries including … It has been used in the treatment of stomach diseases, liver disorders, constipation, bloody diarrhoea, dysentery, children’s fevers, hypotriglyceridaemic, haemorrhoids and skin eruptions [A33162].

  7. Drug

    Omburtamab

    go.drugbank.com/drugs/DB15635
    Investigational

    [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers. … [A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases).

  8. Drug

    Perflubron

    go.drugbank.com/drugs/DB05791
    Investigational

    Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH. … [L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule.

    Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isole
  10. Drug

    Bexotegrast

    go.drugbank.com/drugs/DB16515
    Investigational

    The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical … In addition, the compound is also currently in Phase 2a trials (NCT04565249) for the treatment of COVID-19 related acute respiratory distress syndrome[L31713].